Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback